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Abstract 
 
Purpose 
Although considerable efforts have been made to investigate the effectiveness of 
pharmacological treatments for stuttering, little is known about how the stuttering 
community perceives these treatments. This study aimed to assess and quantify beliefs 
regarding pharmacotherapy for adults who stutter and to establish whether behavioural 
intentions to undertake treatment were related to these beliefs. 
 
Method 
An adapted version of the Beliefs about Medicine Questionnaire was completed by adults 
who stutter. Participants also reported perceptions of their stuttering including its overall 
impact, ratings of previous speech therapy, and behavioural intentions to initiate 
pharmacotherapy and speech therapy in future. 
 
Results 
Necessity and concern beliefs were distributed widely across the sample and in a pattern 
indicating a relatively balanced perception of the benefits and costs of medication 
prescribed specifically for stuttering. Of the study’s measures, the necessity-concerns 
differential most strongly predicted the behavioural intention to initiate pharmacotherapy. 
The overall impact of stuttering predicted intentions to seek both pharmacotherapy and 
speech therapy. Participants reported the likelihood of pursuing pharmacotherapy and 
speech therapy in equal measure. 
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Conclusions 
The theoretical model of medication representations appears to be a useful framework for 
understanding the beliefs of adults who stutter towards the medical treatment of their 
disorder. The findings of this study may be of interest to clinicians and researchers 
working in the field of stuttering treatment and to people who stutter considering 
pharmacotherapy. 
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1. Introduction 
 
Stuttering is a fluency disorder characterised by prolongations, repetitions and blocking 
of speech. These surface behavioural features are typically accompanied by private 
affective and cognitive reactions to the experience of being unable to speak fluently and 
to listener responses to stuttering (Bloodstein & Bernstein Ratner, 2008). Numerous 
studies confirm assumptions that stuttering can limit the speaker’s ability to participate in 
daily communication activities (Sheehan, 1975; Yaruss & Quesal, 2006), that stuttering 
negatively impacts upon quality of life in terms of social, emotional and mental 
functioning (Craig, Blumgart & Tran, 2009), and that the disorder can hinder educational 
and occupational attainment (Daniels, Gabel & Hughes, 2012; Klompass & Ross, 2004). 
 
The onset of stuttering occurs most often during childhood, between the ages of 2 and 5. 
Traditional estimates of incidence and prevalence are around 5% and 1% respectively, 
though in light of recent evidence, Yairi and Ambrose (2013) suggest there may be a case 
for revising these percentage estimates. Nevertheless, the marked difference between 
incidence and prevalence figures reflects the fact that most children who stutter recover 
either with or without treatment (Dworzynski et al., 2007; Mansson, 2000). For stutterers 
whose disorder persists through adolescence and into adulthood, however, the prospects 
of recovery diminish dramatically. 
 
Historically, the principal treatment for stuttering has been speech therapy, and 
approaches vary widely both in their theoretical grounding and in the extent to which 
they aim to ameliorate specific behavioural, affective and cognitive aspects of the 
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disorder. Approaches for young children involve parents in the therapy and can be 
classified as either indirect or direct in nature. The former seeks the general reduction of 
communicative demands on the child in line with their existing capacities for fluency, 
while the latter employs operant conditioning principles, primarily positive 
reinforcement, to facilitate fluent speech (de Sonneville-Koedoot, Stolk, Rietveld & 
Franken, 2015). For adults who stutter, two broad categories of speech therapy exist. The 
first, known as stuttering modification, uses avoidance reduction, desensitisation, gradual 
modification of stuttering behaviour, and alteration of feelings and thoughts towards 
stuttering, and places little emphasis on fluency as a direct objective. By contrast, the 
second approach, termed fluency shaping, aims explicitly to establish speech that is free 
of stuttering by means of behavioural principles, and pays less attention to the emotions 
and attitudes accompanying stuttering. A third category of speech therapy seeks to 
integrate stuttering modification and fluency shaping (Blomgren, 2013; Guitar, 2013; 
Manning, 2010). 
 
Achieving a clear picture on the effectiveness of speech therapy for stuttering has long 
been a challenge for researchers, clinicians and consumers. As indicated above, there 
remains a lack of consensus amongst professionals as to the most effective speech 
therapy for children and adults who stutter. Consequently, there is disagreement about the 
criteria for satisfactory therapy, about the nature of, and indeed the existence of, 
therapeutic phenomena such as the “establishment” of fluency within the clinic and 
“transfer” of fluency beyond it (Sheehan, 1979), and about the most appropriate means of 
measuring therapeutic outcomes (Guntupalli, Kalinowski & Saltuklaroglu, 2006; Quesal, 
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Yaruss & Molt, 2004; St Louis, 2006). As a rule, outcomes for standardised, 
behaviourally-oriented treatments have been published more often than those for 
individualised, psychosocially-oriented treatments. While systematic reviews have 
concluded that speech therapy for stuttering can be effective in reducing observable 
stuttering behaviour and in improving social, affective and cognitive aspects of stuttering 
for specific periods (e.g., Bothe, Davidow, Bramlett & Ingham, 2006), the longer-term 
maintenance of therapeutic gains continues to be a major issue for adults who stutter. Due 
to long reinforcement histories with their stuttering, advanced or “confirmed” people who 
stutter face significant challenges in speech therapy, and relapse during or following 
treatment is commonplace (Bloodstein & Bernstein Ratner, 2008; Craig, 1998; DiLollo, 
Neimeyer & Manning, 2002). It is understandable then that researchers, clinicians and 
people who stutter have looked beyond speech therapy for alternative treatments. 
 
Among a number of modern alternatives are pharmacological treatments of stuttering. 
These have a shorter history in comparison with speech therapy, with the earliest 
published research into medication for stuttering, using stimulants and sedatives, dating 
back to the 1950s (Brady, 1991; Van Riper, 1973). Early pharmacological investigations 
of dopamine antagonists such as haloperidol, used in the treatment of psychosis, have 
shown improvements in the speech fluency of adults who stutter, but due to risks of 
impaired motor function such as tardive dyskinesia, have not been commonly prescribed 
(Ludlow, 2006). Newer-generation dopamine-blocking agents such as risperidone and 
olanzapine, tested in randomised, double-blind, placebo-controlled studies, have also 
shown to relieve behavioural symptoms of stuttering and to pose fewer motor dysfunction 
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risks, although other side effects such as weight gain and sedation are sometimes 
experienced (Maguire, Riley, Franklin & Gumusaneli, 2010). 
 
Adverse side effects associated with medications decrease their tolerability, often cause 
patients to discontinue treatment and so increase the likelihood of relapse. Hence, 
regardless of the disorder, researchers are keen to develop medications which have good 
tolerability profiles. Pagoclone, originally developed to treat anxiety, is one such 
medication and is the first to be tested through the U.S. Food and Drug Administration 
process as a potential treatment for stuttering. In a double-blind, placebo controlled study 
with open label extension, pagoclone was found to reduce stuttering symptoms in 55% of 
the patients in the active medication group, was tolerated well and had high levels of 
patient satisfaction (Maguire et al., 2010). Notably, pagoclone, a selective GABA-A 
partial agonist, was shown to markedly reduce social anxiety, an effect not often 
associated with dopamine antagonist medications. Another relatively well tolerated 
medication, used in the treatment of bipolar disorder and schizophrenia, is asenapine. Its 
effects on developmental stuttering have been examined in three case studies. In these, 
asenapine was clinically observed to improve the fluency of adults who stutter (Maguire, 
Franklin & Kirsten, 2011). In a more recent preliminary investigation, lurasidone, another 
antipsychotic dopamine antagonist, was shown to reduce stuttering symptoms in a sample 
of patients who stutter (Charoensook & Maguire, 2017). 
 
To the authors’ knowledge, at the time of writing, no drug has been formally approved 
for market as a treatment for stuttering. Therefore, prescription of medications for the 
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disorder occurs presently in an “off-label” fashion. At the same time, data from 
neuroscientific research are increasing the understanding of the possible physiological 
basis of stuttering (e.g., Connally, Ward, Howell & Watkins, 2014; Ingham, Grafton, 
Bothe & Ingham, 2012; Sengupta et al., 2017). There is also an impetus to continue 
research on the efficacy of pharmacological therapies. Noting the methodological 
limitations of some studies to date, it has been argued that ongoing research should seek 
to be as rigorous as possible, employing large, carefully selected participant samples in 
randomised controlled trials, and using a range of outcome measures. A further 
recommendation is that the effects of pharmacological treatments are studied in 
comparison and in combination with those of speech therapy (Bothe, Davidow, Bramlett, 
Franic & Ingham, 2006; Maguire et al., 2010). 
 
On the consumer side, anecdotal indications suggest that there is a strong desire among 
some people who stutter for an effective pharmacological treatment, i.e., one designed 
and approved specifically for stuttering (Maguire & Wither, 2010; McCauley & Guitar, 
2010; Miller, 2016). The present study puts this proposition to the test, empirically, by 
examining a range of stuttering-related factors which may influence people who stutter to 
consider a medical treatment, whilst taking into account that people make rather 
complicated decisions about medication based on its perceived health risks and benefits. 
 
According to Horne’s (1997, 2003) theoretical model of medication representations, 
people hold key beliefs towards their health conditions and the medical treatments 
prescribed for these. Beliefs towards a specific treatment can focus on both its necessity 
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in maintaining a person’s health, and also on the concerns a person may have towards a 
medicine’s adverse effects. Thus, the model recognises that individuals differ from each 
other in their perceptions of personal need for prescribed medicines, i.e., some people 
will doubt the necessity of a medicine in maintaining or improving their current health. 
The model also holds that people differ in their sensitivity to the negative consequences, 
i.e., side effects that frequently accompany medication use.  
 
This necessity-concerns framework underlies the Beliefs About Medication 
Questionnaire (BMQ; Horne, Weinman & Hankins 1999), a validated instrument 
designed to quantify patients’ and prospective patients’ cognitive and affective 
representations of medication. It is assumed that individuals weigh up the perceived costs 
of taking a specific medication with the perceived benefits. In some cases, individuals 
will conclude that the benefits outweigh the costs and so will hold a generally positive 
belief towards their medication. In other cases, individuals will perceive a greater cost 
than benefit and this will result in a negative belief. Data from the questionnaire allow 
clinicians and researchers to understand the distribution of beliefs about the necessity of 
prescribed medication and concerns about taking it among specific patient groups. 
 
The BMQ has been used to assess medication beliefs in a range of different chronic 
illness groups. For example, Aikens, Nease, Nau, Klinkman and Schwenk (2005) 
investigated the mental representations of patients with major depressive disorder in 
relation to the patients’ adherence to antidepressant medication. They found that patients 
varied widely according to perceived need for their medication, perceptions of their 
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medication’s harmfulness, and self-reported adherence to their medication. Similarly, 
Menckeberg et al. (2008) assessed asthma patients’ necessity beliefs and concerns about 
their personal use of inhaled corticosteroids and found that these correlated with self-
reported adherence to the medication and actual adherence as indicated objectively by 
pharmacy dispensing records. In both of these studies, participants were categorised as 
either low or high on the BMQ’s necessity and concern scales enabling them to be 
classified overall as belonging to one of four attitudinal groups: accepting (high 
necessity, low concerns), ambivalent (high necessity, high concerns), indifferent (low 
necessity, low concerns), and skeptical (low necessity, high concerns). Adherence to 
medication was highest in the accepting and ambivalent groups, and lowest in the 
indifferent and skeptical participants. (For a meta-analytic review of the application of 
the necessity-concerns framework to a range of illnesses such as coronary heart disease, 
kidney disease, schizophrenia, and HIV/AIDS, see Horne, Chapman, Parham, 
Freemantle, Forbes and Cooper, 2013). 
 
Borrowing from Horne’s (2003) theoretical model of medication representations, the 
present study aimed to assess the balance between necessity and harmfulness beliefs 
towards pharmacological treatments for stuttering within a sample of adults who stutter. 
The study also sought to examine how likely adults who stutter would be to initiate a 
pharmacological treatment for their disorder, speech therapy for their stuttering, and what 
specific factors (e.g., severity, past therapy experiences) would influence their future 
stuttering treatment decisions. Participants were invited to complete an anonymous online 
survey comprising demographic questions, their cognitive and affective representations 
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towards medications for stuttering, the disorder’s impact on their day-to-day lives, and 
their possible behavioural intentions towards medications for stuttering. It was expected 
that the strongest behavioural intentions to seek treatment would be significantly related 
to the BMQ’s necessity-concerns differential, the perceived impact of stuttering on 
participants’ lives, and its perceived severity. 
 
2. Method 
 
2.1 Participants 
This study received ethical approval from the School of Psychological Sciences and 
Health Ethics Committee at the University of Strathclyde, and was conducted in 
accordance with the University’s Code of Practice on Investigations Involving Human 
Beings. Informed consent was sought from participants prior to their commencement of 
the study. Inclusion criteria for participation in the study were twofold: participants 
should be a person who stutters, and aged between 18 and 65 years. Thus, participants 
were self-identifying adults who stutter. Two hundred and thirty four male and female 
individuals completed the online survey. Responses from 4 individuals were excluded 
because they were younger than 18, and data from a further 4 respondents were excluded 
as they were incomplete, leaving a total sample of 226. Respondents were from the 
United Kingdom (59.73%), United States (17.26%), Ireland (7.52%), and Canada 
(4.42%); the remaining participants (11.07%) were from various countries within Europe, 
Oceania, South America, Asia and Africa. Further demographic information relating to 
the respondents is shown in Table 1 and demonstrates that the sample was relatively 
diverse with respect to age and gender as well as marital, parental and employment status. 
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While the vast majority of the sample had previous experience with speech therapy for 
stuttering, few reported experience with prescribed medication for stuttering. 
 
2.2 Materials 
The survey incorporated three published measures and each of these is described below. 
In addition, respondents were asked to indicate the country they lived in, their age of 
stuttering onset, and number of different speech therapy experiences. Perceived success 
with speech therapy (where appropriate) was rated on a 9-point Likert scale with 1 being 
Very Low and 9 Very High. Respondents specified whether or not they had ever taken 
prescribed medication specifically for their stuttering, and for other medical conditions 
which may have affected their stuttering. They also indicated whether or not they were 
presently taking medication for stuttering, mental illness (e.g., depression, anxiety), or a 
serious physical condition (e.g., diabetes, high blood pressure, heart disease). Finally, at 
the end of the survey, respondents were invited to rate the likelihood that they would (i) 
seek a drug treatment for their stuttering in the future, and (ii) seek speech therapy for 
their stuttering in the future. 
 
2.2.1 Beliefs about Medicines Questionnaire (BMQ; Horne, Weinman & Hankins, 1999) 
The BMQ is a two section questionnaire designed to assess the cognitive representation 
of medication use. The BMQ-General comprises eight items and measures beliefs about 
the harmfulness of medicines and their overuse in general. Items measuring harm include 
“Medicines do more harm than good” and items measuring overuse include “Doctors 
place too much trust on medicines”. The BMQ-Specific has 11 items and quantifies 
personal beliefs about the necessity of prescribed medicine and personal concerns about 
  
13 
 
taking medication for specific disorders. This section of the BMQ was adapted for the 
purposes of the present study and was preceded with the reference statement “We would 
like to ask you about your personal views about medicines which could be prescribed for 
your stuttering”. Items measuring necessity included “My ability to speak without 
stuttering, in the short term, would depend upon these medicines” and “Without these 
medicines, I would stutter a lot”. Items measuring concerns included “Having to take 
these medicines would worry me” and “I would sometimes worry about becoming too 
dependent on these medicines”. All responses on the questionnaire are scored on a 5-
point scale from 1 (Strongly disagree) to 5 (Strongly agree) and summed to produce totals 
for each subscale. It is assumed that individuals weigh up the perceived costs of taking 
medication with the perceived benefits. In some cases, individuals will conclude that the 
benefits outweigh the costs and so will hold a generally positive attitude towards 
medication. In other cases, individuals will perceive a greater cost than benefit and this 
will result in a negative attitude. The BMQ allows this attitude to be represented 
numerically by calculating the difference between necessity and concern scores. The 
resulting measure is the necessity-concerns differential. The BMQ’s reliability, criterion-
related and discriminant validity has previously been demonstrated for a number of 
chronic illness groups. 
 
2.2.2 Overall Assessment of the Speaker’s Experience of Stuttering (OASES; Yaruss & 
Quesal, 2008) 
The OASES is a 100-item self-report instrument measuring the overall impact of 
stuttering on a person’s life. It comprises four subscales: general information, reactions to 
stuttering, communication in daily situations, and quality of life. Responses are recorded 
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on a 5-point scale with higher scores indicating greater negative impact of stuttering. 
Respondents are free to skip items that do not apply to them (e.g., individuals not 
currently employed can skip items relating to how much stuttering interferes with aspects 
of their working life). The OASES yields a numerical impact score for each subscale, a 
total impact score and an associated overall impact rating (mild to severe) for each 
respondent. The instrument has been shown to have strong internal consistency 
reliability, test-retest reliability, content validity, and construct validity. 
 
2.2.3 Subjective Screening of Stuttering (SSS research edition; Riley, Riley & Maguire, 
2004) 
The three subscales of the SSS measure perceived stuttering severity, locus of control of 
stuttering behaviour, and avoidance from the perspective of the person who stutters. 
Across 22 items, respondents rate these distinct aspects of the stuttering experience with 
different audiences (close friend, authority figure, telephone) during the past week on a 9-
point scale. For example, on the item ‘How would you score your speech with the 
following audiences during the last week?’ the response scale ranges from 1 (Relatively 
fluent) to 9 (Severe stuttering). Items relating to experiences with a close friend are 
included for comparison purposes, but are not scored due to usually being less 
representative of stuttering difficulty. The present study employed the severity (4 items) 
and locus of control (9 items) scales. Scores are calculated by summing the ratings for the 
relevant items in each subscale. Higher scores represent greater severity and greater 
external locus of control. Authors of the SSS report reasonable content and criterion-
related validity for the instrument. 
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2.3 Procedure 
The study was a web-based survey. Web surveys have some advantages over traditional 
survey methods with respect to reducing cost, simplifying the process of data collection 
and data inputting, accessing hard-to-reach populations, and enabling respondents to 
remain anonymous (Alessi & Martin, 2010; Hash & Spencer, 2009; Temple & Brown, 
2012). The study was promoted via announcements on the websites, and associated social 
media sites, of the following national stuttering self-help organisations: British 
Stammering Association, National Stuttering Association, Irish Stammering Association, 
Canadian Stuttering Association, and British Columbia Association of People Who 
Stutter. In addition, invitations to complete the survey were distributed by email to local 
stammering support groups within the UK and to the email mailing list of the National 
Stuttering Association. The survey was accessed via a direct web link. Respondents were 
first presented with information on the purposes of the study and the survey’s content. In 
the interests of candour and validity, responses were anonymous. Upon completion of the 
survey, respondents were presented with a written debrief and thanked for their 
participation. 
 
2.4 Data analyses 
Descriptive (mean, standard deviation, range) and frequency statistics were calculated for 
each of the survey’s measures. The internal consistency of the BMQ, OASES, and SSS 
subbscales were assessed by means of Cronbach’s alpha. Pearson’s r correlation 
coefficients were computed for all key variables and multivariate regression analyses 
were conducted to examine which of the study’s factors best predicted the intention to 
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undertake pharmacological treatment and speech therapy. Each participant was 
categorised as accepting, indifferent, skeptical, or ambivalent towards pharmacotherapy 
for stuttering according to their necessity and concern scores on the BMQ-Specific. The 
differences in behavioural intentions between these groups were assessed using a one-
way between-subjects ANOVA and Bonferroni post-hoc tests. Lastly, a paired t-test was 
used to examine the relative strength of behavioural intentions towards pharmacotherapy 
and speech therapy within the survey’s sample. 
 
3. Results 
 
The mean scores for impact of stuttering, severity, locus of control and medication beliefs 
are presented in Table 1. Also presented are speech therapy success ratings and ratings 
for the likelihood of seeking drug treatment and speech therapy for stuttering in future. 
The frequency distributions of OASES impact ratings are comparable to those in Yaruss 
and Quesal’s (2008) standardisation sample (N=173). 
 
Cronbach’s alpha coefficients for the four OASES subscales were >.90. The alpha 
coefficients for the severity and locus of control subscales of the SSS were .86 and .93 
respectively. The coefficients for the BMQ harm and overuse subscales were .74 and .78 
respectively, and for the BMQ necessity and concern scales were .85 and .80. These 
figures indicate high internal reliability within each of the study’s published measures. 
 
Table 2 shows the correlations between the study’s various measures. Age correlated 
negatively with impact, severity, locus of control and the likelihood of seeking speech 
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therapy. As age increased, the likelihood of seeking speech therapy for stuttering 
decreased. Rated success with previous speech therapy correlated negatively with impact, 
severity, locus of control, necessity and the likelihood of seeking drug treatment. As 
speech therapy success ratings increased, the likelihood of seeking drug treatment 
decreased. Impact of stuttering, severity, and locus of control correlated positively with 
each other, and these three measures all correlated positively with the likelihood of 
seeking both types of treatment. Necessity correlated positively with the likelihood of 
seeking drug treatment. 
 
A multiple linear regression analysis was used to test if the rated success of previous 
speech therapy, impact of stuttering, severity, locus of control, and necessity-concern 
differential would predict the likelihood of seeking a drug treatment in future. The overall 
model was significant: adjusted R2= .41, F(5, 194) = 28.47, p <.001. Both the impact of 
stuttering (B=.69, SEB=.26, β=.26, p =.008) and the necessity-concern differential 
(B=.13, SEB=.02, β=.45, p <.001) significantly predicted likelihood of seeking a drug 
treatment. None of the other variables, rated success of previous speech therapy (p = .17), 
severity (p = .40), or locus of control (p = .49) significantly predicted likelihood of 
seeking a drug treatment. 
 
A further regression was run to test if the same variables would predict the likelihood of 
seeking speech therapy. Again, the overall model was significant: adjusted R2= .10, F(5, 
194) = 5.48, p <.001. Both the rated success of previous speech therapy (B=.20, SEB=.07, 
β=.23, p =.004) and the impact of stuttering (B=.67, SEB=.30, β=.27, p =.03) significantly 
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predicted likelihood of seeking speech therapy. None of the other variables, severity (p = 
.06), locus of control (p = .85), or necessity-concern differential (p = .09) significantly 
predicted likelihood of seeking speech therapy. 
 
The necessity and concern dimensions were split at the scale midpoints creating four 
belief groups within the sample of participants: accepting (high necessity, low concerns, 
n = 36), indifferent (low necessity, low concerns, n = 62), skeptical (low necessity, high 
concerns, n = 75), and ambivalent (high necessity, high concerns, n = 53). As confirmed 
by a χ2 test of goodness-of-fit, participants were not equally distributed across the four 
groups, χ2 (3, n = 226) = 14.25, p = .003. The belief groups are presented in Figure 1. 
 
A one-way between-subjects ANOVA showed that likelihood of seeking a drug treatment 
varied significantly by belief group: F(3,222) = 23.43, p <.001, 2p = .24. Bonferroni 
post-hoc tests indicated that the accepting group had significantly higher ratings than 
each of the other three groups (p = .02 or smaller). Ambivalent and indifferent 
participants were significantly more likely to seek a drug treatment than skeptical 
participants (p <.001). There was no significant difference between the ambivalent and 
indifferent groups. Figure 2 illustrates these effects. 
 
A paired t-test showed there was no significant difference between ratings of the 
likelihood of seeking a drug treatment and seeking speech therapy in future: t = 0.39, df = 
225, p = .70, two-tailed. 
 
  
19 
 
4. Discussion 
 
A key aim of the present study was to quantify the cognitive and affective representations 
of adults who stutter regarding pharmacotherapy for their disorder. Data from the BMQ 
indicate that adults who stutter share typical beliefs about medications in general, i.e., 
beliefs about harmfulness and overprescription that are consistent with those of patients 
with other chronic disorders (e.g., Menckeberg et al., 2008). There is nothing in these 
data to suggest that adults who stutter are particularly distinctive in their general beliefs 
towards medicines. Of primary interest in the present study, however, are data from the 
BMQ on necessity and concerns regarding medicines specifically prescribed for 
stuttering. 
 
The necessity-concerns differential is the difference between the necessity and concerns 
scores (with a possible range of -20 to 20) and is intended to represent the outcome of 
cost-benefit analyses that people perform with respect to medication for a specific 
disorder. Positive scores indicate that patients perceive the benefits of their medication to 
outweigh the costs; negative scores result where patients perceive greater cost than 
benefit (Horne & Weinman, 1999). In the present study, the mean necessity-concerns 
differential was midway between the two extremes (mean=-2.33), and only marginally 
negative suggesting that, overall, beliefs towards the benefits and costs of medication for 
stuttering were quite evenly balanced. 
 
A further aim of this study was to assess the behavioural intentions of adults who stutter 
towards the uptake of pharmacological treatments and speech therapy for stuttering in the 
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future. The vast majority of participants in the present study, almost 90%, had previous 
experience of speech therapy for stuttering, reported modest levels of success with this 
treatment option, and reported a considerable negative impact of stuttering on their lives. 
Given these experiences and given that stuttering in adulthood can be resistant to change 
and therapeutic gains within speech therapy can be prone to the dynamics of relapse 
(Bloodstein & Bernstein Ratner, 2008), it follows that adults who stutter may be open to 
alternative treatments, including pharmacotherapy (McCauley & Guitar, 2010). This 
proposition appears to be borne out by the results: within the present sample, behavioural 
intentions to undertake pharmacotherapy were as strong as those to initiate the more 
established option of speech therapy. 
 
It was hypothesised that behavioural intentions to seek pharmacotherapy in future would 
be predicted by the perceived impact of stuttering on participants’ lives, self-reported 
severity, locus of control, and the necessity-concerns differential. Consistent with this 
prediction, both the overall impact of stuttering and the necessity-concerns differential 
significantly predicted the likelihood of seeking a drug treatment. Of these two measures, 
the necessity-concerns differential was the strongest predictor. These findings indicate 
that negative experiences of the stuttering disorder, those involving cognitive and 
affective reactions to stuttering, daily communication difficulties and decreased quality of 
life, i.e., those beyond the observable aspects of speech fluency, are likely to be factors 
motivating individuals who stutter to pursue a pharmacological treatment. These findings 
also suggest that medication beliefs, those reflecting the balance of perceived benefits 
and perceived risks of medication for stuttering are predictive of intentions to seek 
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treatment. More specifically, cost-benefit analyses are most strongly related to 
behavioural intentions to pursue pharmacotherapy where the former result in appraisals in 
which the benefits of the medication for stuttering are perceived to outweigh the costs. 
 
The latter result is consistent with previous research investigating the relationship 
between medication beliefs and the uptake of medical treatments in a range of conditions. 
For example, necessity beliefs and concerns have been found to predict the uptake of 
highly active antiretroviral therapy in HIV patients as well as subsequent adherence to the 
medicine (Horne, Cooper, Gellaitry, Leake Date & Fisher, 2007). The present findings 
are also in line with those of earlier studies which found that injecting and smoking drug 
users who perceived a need for drug abuse treatment had a greater likelihood of entering 
such treatment (Siegal, Falck, Wang & Carlson, 2002; Zule & Desmond, 2000). 
 
Significant differences between the accepting, indifferent, ambivalent, and skeptical 
beliefs groups were found for the behavioural intention to seek pharmacotherapy for 
stuttering. As might be expected, participants in the accepting group were most likely, 
and participants in the skeptical group least likely, to seek a drug treatment. This is a 
further indication that beliefs about medications for stuttering vary considerably within 
the stuttering population and that these seem to be directly associated with subsequent 
decisions about treatment. As noted previously, a similar pattern of results has been 
found in studies investigating adherence to medical treatments in samples of patients with 
major depressive disorder and asthma (Aikens et al., 2005; Menckeberg et al., 2008). 
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The self-reported overall impact of stuttering on the participants’ lives, as measured by 
the OASES instrument, predicted the behavioural intention to seek speech therapy for 
stuttering in the future, as well as pharmacotherapy. This suggests that functional 
communication difficulties, unseen aspects of the stuttering disorder, and quality of life 
issues are motivating factors for stuttering therapy more generally, and not just for one or 
other treatment option. The other factor predicting the intention to seek speech therapy, 
though not pharmacotherapy, in the present sample, was the rated success of previous 
speech therapy. This finding would tend to suggest that some adults who stutter recognise 
the successful management of stuttering as a long-term process, one which may require a 
return to the clinic for follow-up therapy (Manning, 2010). 
 
A methodological limitation to this study is that participants’ behavioural intentions 
towards future stuttering treatment were assessed rather than their actual behaviour. On 
the basis of the available data, it is not possible to determine the extent to which the 
expressed intentions would result in subsequent behaviour, i.e., the initiation of 
pharmacotherapy or speech therapy, and this limits the conclusions that can be drawn. 
However, a large body of social psychological theory and research has informed our 
understanding of the intentions-behaviour relationship sufficiently to enable a reasoned 
prediction of behaviour in the present case assuming certain conditions are met. 
 
According to the theory of planned behaviour (Ajzen, 1991), the strength of a person’s 
intention to perform a specific behaviour is contingent upon their attitude toward the 
behaviour, perceived social pressure to engage in the behaviour, and the person’s 
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perception of their ability to perform the behaviour. Where attitudes and subjective norms 
are favourable, and perceived behavioural control is strong, intentions to perform the 
behaviour in question should be strong, and where a person has a sufficient degree of 
actual control over the behaviour, intentions should lead to behaviour. This theory has 
much empirical support. In a meta-analysis of 185 correlational studies, it was found to 
explain 27% of the variance in behaviour and intentions were found to be reliably 
associated with behaviour (Armitage & Conner, 2001). A further review of experimental 
evidence concluded that intention-behaviour relations are often more modest than earlier 
research assumed and are strongest where people have control over their behaviour 
(Webb & Sheeran, 2006). Overall then, applied to the case of individuals seeking 
stuttering treatment, based on prior research, we might assume that if a person holds a 
positive attitude towards a specific stuttering treatment, if subjective norms relating to the 
treatment are favourable, and the person has volitional control over treatment initiation, 
then they should initiate the treatment. 
 
Implicit within the present study’s procedure is that speech therapy and pharmacotherapy 
for stuttering are mutually exclusive treatment options. While this has tended to have 
been the case historically, an emerging possibility is that speech and language 
pathologists might work collaboratively with physicians in offering people who stutter a 
treatment combining both therapies. Multidisciplinary and interdisciplinary team working 
within medicine and rehabilitation have a considerable history (Rokusek, 1995) and 
speech and language pathologists already work in such a fashion with allied health 
professionals and family members (e.g., Farneti & Consolmagno, 2007; Shapiro, 1999). 
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In a collaborative approach to stuttering, therapy would be tailored to the individual 
needs of the adult clients. The speech and language pathologist would apply their 
expertise as usual to speech assessment and the management of stuttering behaviours and 
emotional reactions. A neurologist or psychiatrist would make decisions about 
appropriate medications for the reduction of stuttering, taking into account physical 
comorbidities and accompanying medications and/or recreational drugs which might 
impair stuttering treatment, and would monitor for possible side effects of the prescribed 
medication. It is argued that a psychiatrist might offer additional expertise in terms of 
cognitive behavioural therapy (Ludlow, 2006; Maguire et al., 2010; Maguire, Yeh & Ito, 
2012). 
 
4.1 Conclusion 
To the authors’ knowledge, this is the first study to systematically investigate how 
members of the stuttering community perceive pharmacotherapy, an emerging 
intervention for the disorder of stuttering, and what personal factors might motivate 
pursuit of this treatment. Following previous research with patients across a range of 
chronic conditions, Horne’s (2003) theoretical model of medication representations was 
used to explore differences between adults who stutter in their beliefs about medication 
for their disorder. It was shown that the necessity-concerns framework and data from the 
BMQ-Specific can provide clinicians and researchers working with adults who stutter an 
explanatory model for understanding their cognitive and affective representations 
regarding pharmacotherapy and their behavioural intentions to seek such treatment. The 
BMQ-Specific may also be a means of predicting subsequent uptake and adherence 
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behaviours in people who stutter, an idea that could be tested in future research. 
Knowledge that a prospective patient is accepting, indifferent, ambivalent or skeptical 
towards a specific medication for stuttering could usefully inform pre-treatment 
consultations and enhance communication and co-operation between patients and 
practitioners. The findings of this study also show that the OASES, an instrument 
designed to measure the entirety of the stuttering experience, may have utility in 
predicting the behaviour of people who stutter considering a medical treatment for 
stuttering. Building on the present study, further research could assess the attitudes of 
people who stutter towards a combined approach of speech therapy and 
pharmacotherapy, an approach that may prove to be more attractive to consumers than 
either therapy alone. 
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Table 1. Demographic information for respondents (N=226) and descriptive statistics for survey measures. 
Demographic information  
Age in years  
   Mean (SD), range 35.65 (12.57) 18-65 
Sex (male), % 65.04 
Married (or with significant other), % 49.11 
Children, % 33.19 
Currently employed, % 76.11 
Stuttering characteristics  
Onset age of stuttering in years  
   Mean (SD), range 5.25 (3.08) 0-17 
OASES total mean (SD) 2.96 (0.70) 
OASES impact ratings, %  
   Mild 2.21 
   Mild/Moderate 13.72 
   Moderate 34.51 
   Moderate/Severe 36.73 
   Severe 12.83 
Subjective Screening of Stuttering (SSS)  
   Severity, mean (SD) 14.20 (5.59) 
   Locus of control, mean (SD) 30.62 (13.21) 
Speech therapy experiences  
Previous speech therapy experience, % 88.5 
Currently receiving speech therapy, % 13 
No. of speech therapy experiences  
   Mean (SD), range 3.08 (1.99) 1-15 
Speech therapy success ratings  
   Mean (SD), range 4.07 (2.13) 1-9 
Medication experiences and beliefs  
Previous stuttering medication experience, % 6.64 
Presently taking medication, %  
   for stuttering 2.21 
   for mental illness 16.37 
   for serious physical condition 11.50 
Beliefs about Medication Questionnaire (BMQ)  
   General-Overuse, mean (SD) 11.80 (3.34) 
   General-Harm, mean (SD) 9.42 (2.93) 
   Specific-Necessity, mean (SD) 12.69 (4.15) 
   Specific-Concerns, mean (SD) 15.03 (4.46) 
   Necessity-concerns differential, mean (SD) -2.33 (6.45) 
Likelihood of seeking treatment for stuttering  
   Drug treatment, mean (SD) 4.13 (1.89) 
   Speech therapy, mean (SD) 4.07 (1.77) 
 
OASES = Overall Assessment of the Speaker’s Experience of Stuttering 
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Table 2. Pearson’s r correlations. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                        *p < .05, **p < .01, ***p < .001 
 2 
 
3 4 5 6 7 8 9 10 
1. Age .170* 
 
-.013 -.227** -.151* -.245*** -.042 .004 -.089 -.326*** 
2. Number of speech therapy 
experiences 
- 
 
.002 -.058 .118 -.017 .001 .060 .057 -.152* 
3. Rated success of speech therapy - - -.515*** 
 
-.234** -.241** -.314*** .122 -.350*** .091 
4. Impact of stuttering 
 
- - - .637*** .724*** .526*** -.145* .499*** .253*** 
5. Severity 
 
- - - - .733*** .355*** -.182** .341*** .263*** 
6. Locus of control 
 
- - - - - .409*** -.191** .349*** .234*** 
7. Necessity - - - - - 
 
- -.120 .478*** .126 
8. Concerns - - - - - 
 
- - -.398*** .104 
9. Reported likelihood of drugs - - - - - 
 
- - - .153* 
10. Reported likelihood of speech 
therapy 
- - - - - - 
 
- - - 
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Figure 1. Medication for stuttering beliefs groups (percentage of sample in parentheses). 
 
 
 
Figure 2. Likelihood of seeking a drug treatment for stuttering by beliefs group. 
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